MOTS-c Half-Life & Pharmacokinetics — Research Guide (2026)

Research-use only. This guide summarises published pharmacokinetic (PK) data on MOTS-c for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.

MOTS-c is classified as a Mitochondrial-derived peptide (16 amino acids, encoded within 12S rRNA). Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.

At-a-Glance Pharmacokinetics

| Parameter | MOTS-c | | --- | --- | | Classification | Mitochondrial-derived peptide (16 amino acids, encoded within 12S rRNA) | | Serum half-life | Reported serum half-life of approximately 30–60 minutes in rodent PK studies; longer functional duration due to intracellular accumulation in mitochondria. | | Tmax | Tmax of ~30 minutes following subcutaneous or intramuscular administration in published animal studies. | | Validated routes | Subcutaneous and intraperitoneal routes dominate the published preclinical literature. | | Bioavailability | High subcutaneous bioavailability in animal PK data; oral bioavailability is negligible. | | Clearance | Renal clearance of low-molecular-weight fragments; intracellular pool turns over with normal mitochondrial protein dynamics. |

Serum Half-Life

Reported serum half-life of approximately 30–60 minutes in rodent PK studies; longer functional duration due to intracellular accumulation in mitochondria.

Tissue vs Serum

Pharmacodynamic effects on AMPK signalling persist for hours beyond serum clearance, consistent with mitochondrial uptake.

The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For MOTS-c, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.

Time to Peak (Tmax)

Tmax of ~30 minutes following subcutaneous or intramuscular administration in published animal studies.

Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.

Routes of Administration

Subcutaneous and intraperitoneal routes dominate the published preclinical literature.

Bioavailability across routes: High subcutaneous bioavailability in animal PK data; oral bioavailability is negligible.

Clearance & Metabolism

Renal clearance of low-molecular-weight fragments; intracellular pool turns over with normal mitochondrial protein dynamics.

Key Pharmacokinetic Takeaways

• First-characterised mitochondrial-derived peptide with documented endocrine activity
• Serum PK underestimates functional duration due to mitochondrial intracellular accumulation
• Frequently dosed every other day in published animal metabolic models
• Pharmacokinetic data supports its use as a reference mitochondrial signalling peptide

Frequently Asked Questions

What is the half-life of MOTS-c? Reported serum half-life of approximately 30–60 minutes in rodent PK studies; longer functional duration due to intracellular accumulation in mitochondria.

How quickly does MOTS-c reach peak concentration? Tmax of ~30 minutes following subcutaneous or intramuscular administration in published animal studies.

Which routes of administration are validated in published research? Subcutaneous and intraperitoneal routes dominate the published preclinical literature.

Does MOTS-c accumulate with repeat dosing? Renal clearance of low-molecular-weight fragments; intracellular pool turns over with normal mitochondrial protein dynamics. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.

Is oral bioavailability meaningful for MOTS-c? High subcutaneous bioavailability in animal PK data; oral bioavailability is negligible.

Related Research

• Reconstitution & storage protocols — see the MOTS-c reconstitution guide for vial handling that preserves the PK profile described above.
• Dosing protocols research — see the MOTS-c dosing protocols article for how PK parameters translate into scheduling decisions.
• Mechanism of action — see the MOTS-c mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.

---

*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*